NJ drug company execs charged with insider trading
by AP News Now
November 19, 2012 03:45 PM | 1070 views | 0 0 comments | 5 5 recommendations | email to a friend | print
NEWARK, N.J. (AP) — Two pharmaceutical company executives are among six people charged in what federal authorities in New Jersey are calling a five-year insider trading scheme.

John Lazorchak was director of financial reporting at Celgene Corp. and Mark Cupo held a similar position at Sanofi-Aventis.

The U.S. attorney’s office in New Jersey says that between 2007 and 2012, Lazorchak and Cupo passed privileged information on their companies’ merger and acquisition plans, financial results and regulatory applications to others who would make stock trades.

The scheme allegedly reaped $1.4 million.

Lazorchak, Cupo and the others are charged with conspiracy and multiple counts of securities fraud. Each securities fraud count carries a 20-year maximum prison sentence.

They were scheduled to appear in federal court in Newark on Monday afternoon. Their attorneys were in court and unavailable for comment.

Comments
(0)
Comments-icon Post a Comment
No Comments Yet
*We welcome your comments on the stories and issues of the day and seek to provide a forum for the community to voice opinions. All comments are subject to moderator approval before being made visible on the website but are not edited. The use of profanity, obscene and vulgar language, hate speech, and racial slurs is strictly prohibited. Advertisements, promotions, and spam will also be rejected. Please read our terms of service for full guides